PHOENIX, Jan. 31, 2017 -- Global Water Resources, Inc. (NASDAQ:GWRS), (TSX:GWR), a pure-play water resource management company, has declared, under its dividend policy, a monthly cash dividend in the amount of $0.0225 per common share (an annualized amount of $0.27 per share), which will be payable on February 28, 2017, to holders of record at the close of business on February 14, 2017.
About Global Water Resources, Inc.
Global Water Resources, Inc. is a comprehensive water resource management company based in Phoenix, Arizona. It manages the entire water cycle by owning and operating water, wastewater and recycled water utilities. For more information about Global Water Resources, visit www.gwresources.com.
Company Contact for Global Water Resources Michael J. Liebman Chief Financial Officer and Corporate Secretary (480) 999-5104 [email protected] Investor Relations for Global Water Resources: Ronald A. Both CMA (949) 432-7566 [email protected]


Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Italy Fines Apple €98.6 Million Over App Store Dominance
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



